Literature DB >> 29078136

Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells.

Xuguang Chen1, Alireza Nomani1, Niket Patel1, Faranak S Nouri1, Arash Hatefi2.   

Abstract

Vectors used for stem cell transfection must be non-genotoxic, in addition to possessing high efficiency, because they could potentially transform normal stem cells into cancer-initiating cells. The objective of this research was to bioengineer an efficient vector that can be used for genetic modification of stem cells without any negative somatic or genetic impact. Two types of multifunctional vectors, namely targeted and non-targeted were genetically engineered and purified from E. coli. The targeted vectors were designed to enter stem cells via overexpressed receptors. The non-targeted vectors were equipped with MPG and Pep1 cell penetrating peptides. A series of commercial synthetic non-viral vectors and an adenoviral vector were used as controls. All vectors were evaluated for their efficiency and impact on metabolic activity, cell membrane integrity, chromosomal aberrations (micronuclei formation), gene dysregulation, and differentiation ability of stem cells. The results of this study showed that the bioengineered vector utilizing VEGFR-1 receptors for cellular entry could transfect mesenchymal stem cells with high efficiency without inducing genotoxicity, negative impact on gene function, or ability to differentiate. Overall, the vectors that utilized receptors as ports for cellular entry (viral and non-viral) showed considerably better somato- and genosafety profiles in comparison to those that entered through electrostatic interaction with cellular membrane. The genetically engineered vector in this study demonstrated that it can be safely and efficiently used to genetically modify stem cells with potential applications in tissue engineering and cancer therapy.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell transfection; Genotoxicity; Nanoparticles; Non-viral; Stem cells; Vector engineering

Mesh:

Substances:

Year:  2017        PMID: 29078136      PMCID: PMC5671363          DOI: 10.1016/j.biomaterials.2017.10.028

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  48 in total

1.  Structure and function correlation in histone H2A peptide-mediated gene transfer.

Authors:  Danuta Balicki; Christopher D Putnam; Puthupparampil V Scaria; Ernest Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

2.  Induced transgene expression for the treatment of solid tumors by hematopoietic stem cell-based gene therapy.

Authors:  F Noyan; I Avedillo Díez; M Hapke; C Klein; R A Dewey
Journal:  Cancer Gene Ther       Date:  2012-03-09       Impact factor: 5.987

Review 3.  Rationale of genotoxicity testing of nanomaterials: regulatory requirements and appropriateness of available OECD test guidelines.

Authors:  David B Warheit; E Maria Donner
Journal:  Nanotoxicology       Date:  2010-12       Impact factor: 5.913

4.  Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells.

Authors:  Sriramchandra S Mangipudi; Brenda F Canine; Yuhua Wang; Arash Hatefi
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939

5.  Production of low-expressing recombinant cationic biopolymers with high purity.

Authors:  Xuguang Chen; Alireza Nomani; Niket Patel; Arash Hatefi
Journal:  Protein Expr Purif       Date:  2017-03-16       Impact factor: 1.650

6.  Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides.

Authors:  Faranak S Nouri; Xing Wang; Xuguang Chen; Arash Hatefi
Journal:  Pharm Res       Date:  2015-03-31       Impact factor: 4.200

Review 7.  Polycation-mediated integrated cell death processes.

Authors:  Ladan Parhamifar; Helene Andersen; Linping Wu; Arnaldur Hall; Diana Hudzech; Seyed Moien Moghimi
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

8.  Gene transfer using a novel fusion protein, GAL4/invasin.

Authors:  R W Paul; K E Weisser; A Loomis; D L Sloane; D LaFoe; E M Atkinson; R W Overell
Journal:  Hum Gene Ther       Date:  1997-07-01       Impact factor: 5.695

Review 9.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

Review 10.  Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity.

Authors:  A Christy Hunter
Journal:  Adv Drug Deliv Rev       Date:  2006-09-28       Impact factor: 15.470

View more
  4 in total

Review 1.  Non-viral gene delivery systems for tissue repair and regeneration.

Authors:  Pan Wu; Haojiao Chen; Ronghua Jin; Tingting Weng; Jon Kee Ho; Chuangang You; Liping Zhang; Xingang Wang; Chunmao Han
Journal:  J Transl Med       Date:  2018-02-15       Impact factor: 5.531

Review 2.  Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration.

Authors:  Wen-Bo Nie; Dan Zhang; Li-Sheng Wang
Journal:  Drug Des Devel Ther       Date:  2020-03-26       Impact factor: 4.162

Review 3.  Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy.

Authors:  Arbi Aghali
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 4.  Mesenchymal Stem Cells Engineered by Nonviral Vectors: A Powerful Tool in Cancer Gene Therapy.

Authors:  Yuan Ding; Chenyang Wang; Zhongquan Sun; Yingsheng Wu; Wanlu You; Zhengwei Mao; Weilin Wang
Journal:  Pharmaceutics       Date:  2021-06-21       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.